Reducing the Deadliest Ovarian Cancer by Nearly 80% Doesn't Require Removing Ovaries

Most ovarian cancer screenings catch nothing. There's no mammogram equivalent, no reliable early test, just a disease that tends to announce itself after it's already everywhere. A study out of British Columbia just landed with real weight: removing the fallopian tubes during an unrelated pelvic surgery cut the risk of the deadliest type of ovarian cancer by nearly 80%. No ovaries removed. No early menopause. Just two tubes, and apparently most of the problem.

The procedure is called opportunistic bilateral salpingectomy, or OBS, which sounds like something offered at a very niche wellness spa. In reality it is a straightforward add-on: if a patient is already having a hysterectomy or another pelvic surgery and does not plan to have more children, the surgeon removes the fallopian tubes while already in there. The ovaries stay. The hormones stay. The cancer risk, according to a study of more than 85,000 patients tracked across more than a decade, largely does not.

Published Feb. 2 in JAMA Network Open, the research offers strong evidence that OBS lowers ovarian cancer risk. The OBS group showed a hazard ratio of 0.22 for serous ovarian cancer, meaning those patients developed it at about one-fifth the rate. Among patients without fallopian tubes who did develop ovarian cancer, the deadliest subtype, high-grade serous carcinoma, dropped from 68% of cases historically to just 23%.

Ovarian cancer has no reliable early-detection screen, so it is usually found late, when it is hardest to treat. That is the context that makes this finding land.

Surgeons had access to the fix for decades. They just were not reaching for it.

Read the full story at Ovarian Cancer Research Alliance, February 5, 2026

Hot Take: Surgeons spent decades investigating the ovaries. The confession came from the fallopian tubes.